Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNPH1 | O43598 | 1/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 9/20 | 0.73 |
| ▸ | TP53 | P04637 | 1/20 | 0.73 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.73 |
| ▸ | NT5E | P21589 | 1/20 | 0.70 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.69 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.69 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.64 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.64 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24201476 | 0.93 | DNPH1 (0.65) | DNPH1ADORA3TP53SLC29A1TDP1 | |
| SCHEMBL1389413 | 0.92 | ADORA3 (0.64) | DNPH1ADORA3TP53SLC29A1TDP1 | |
| SCHEMBL1389703 | 0.92 | DNPH1 (0.63) | DNPH1ADORA3TP53SLC29A1TDP1 | |
| SCHEMBL14394700 | 0.88 | P2RY12 (0.64) | DNPH1P2RX3P2RX2 | |
| SCHEMBL13902897 | 0.88 | P2RY12 (0.64) | DNPH1P2RX3P2RX2 | |
| SCHEMBL918835 | 0.88 | ADORA3 (0.59) | DNPH1ADORA3TP53SLC29A1TDP1 | |
| SCHEMBL918126 | 0.88 | DNPH1 (0.58) | DNPH1ADORA3TP53SLC29A1TDP1 | |
| SCHEMBL13268857 | 0.87 | ADORA3 (0.81) | DNPH1ADORA3TP53SLC29A1TDP1 | |
| SCHEMBL13957724 | 0.85 | DNPH1 (1.00) | DNPH1ADORA3TP53SLC29A1TDP1 | |
| SCHEMBL14700471 | 0.85 | DNPH1 (1.00) | DNPH1ADORA3TP53SLC29A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252919-B2 | 2′-hydroxy-protected ribonucleoside derivative and production method thereof | KANEKA CORPORATION (JP) | 2012-08-28 | — | — | US | disclosed |
| US-20110009609-A1 | 2'-HYDROXY-PROTECTED RIBONUCLEOSIDE DERIVATIVE AND PRODUCTION METHOD THEREOF | KANEKA CORPORATION (JP) | 2011-01-13 | — | — | US | disclosed |
| EP-2258709-A1 | 2'-HYDROXYL-PROTECTED RIBONUCLEOSIDE DERIVATIVE AND MANUFACTURING METHOD OF SAME | Kaneka Corporation (JP) | 2010-12-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009609-A1 | 2'-HYDROXY-PROTECTED RIBONUCLEOSIDE DERIVATIVE AND PRODUCTION METHOD THEREOF | RNASEL, RNASEH1, NUDT1 | DNPH1 569/4885ADORA3 480/4885TP53 3962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.